1. Overview of targeting DDR dysfunction in cancer2. DNA damage cell cycle checkpoints3. DNA repair, defects in cancer and their exploitation4. MMR defects, mutator phenotype5. SUMO and ubiquitination and other epigenetic and post-translational mechanisms6. Targeting with immune checkpoint inhibitors7. Overview and use of biomarkers in clinical trials8. Poster
